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Abstract
The identification of specific genetic (presenilin-1 [PS1] and amyloid precursor protein [APP]
mutations) and environmental factors responsible for Alzheimer’s disease (AD) has revealed evi-
dence for a shared pathway of neuronal death. Moreover, AD-specific cell defects may be observed
in many other nonneuronal cells (e.g., lymphocytes). Thus, lymphocytes may serve as a cellular
system in which to study risk factors of sporadic, as well as genetic AD in vivo. The aim of our
present study was to clarify whether lymphocytes bearing genetic or sporadic risk factors of AD
share an increased susceptibility to cell death. Additionally we examined whether a cell type-
specific vulnerability pattern was present and how normal aging, the main risk factor of sporadic
AD, contributes to changes in susceptibility to cell death. Here, we report that lymphocytes affected
by sporadic or genetic APPand PS1 AD risk factors share an increased vulnerability to cell death
and exhibit a similar cell type-specific pattern, given that enhanced vulnerability was most strongly
developed in the CD4+ T-cell subtype. In this paradigm, sporadic risk factors revealed the high-
est impact on cell type-specific sensitivity of CD4+ T cells to apoptosis. In contrast, normal aging
results in an increased susceptibility to apoptosis of both, CD4+ and CD8+ T cells.
Index Entries:Transgenic mice; presenilin-1; amyloid precursor protein (APP); lymphocytes;
AD patients; apoptosis.
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Introduction
Apoptosis is of particular interest in aging, as it
is thought to play an important role in various age-
related neurodegenerative diseases. Alzheimer’s
disease (AD) is the leading cause of age-related
dementia, characterized by deposition of β-amyloid
(Aβ) plaques, accumulation of intracellular neu-
rofibrillary tangles, and pronounced neuronal cell
loss. Importantly, aging represents the main risk
factor of sporadic AD. About 10% of AD patients
suffer from an autosomal dominant inheritable vari-
ant of AD. Three genes are causatively linked to the
pathogenesis of early-onset familial AD (FAD)
forms. In addition to the genes encoding for PS1 on
chromosome 14 and presenilin-2 (PS2) on chromo-
some 1, mutations in the APPgene on chromosome
21 account for FAD cases. Despite the fact that neu-
ronal death is a central lesion in AD, the mechanism
of how FAD-linked mutants cause neuronal cell
death is still not clearly understood. One potential
mechanism underlying the neurotoxicity of these
FAD mutants is the generation of amyloid-β (Aβ),
a 39- to 43-amino acid long peptide representing the
major constituent of senile plaques in the brains of
AD patients, owing to an altered proteolytic pro-
cessing of APP. Although significant progress has
been made in our understanding of the proteolytic
processing of APP and the secretion of Aβ peptide,
the mechanisms for the accumulation of Aβdeposits
and their role in AD pathogenesis remains a matter
of speculation (Glabe, 2000; Sambamurti et al., 2002).
Furthermore, there is growing evidence that dis-
turbances in the tight regulation of apoptosis may
contribute to the progressive neuronal loss in AD
brain (Anderson et al., 1996; Cotman, 1998; Stadel-
mann et al., 1999). Several recent findings have
linked Aβ toxicity (Loo et al., 1993) and increased
Aβ production resulting from FAD-related APP or
PS1 mutations to cell death (Czech et al., 2000; Matt-
son et al., 2001; Selkoe, 2001). Recent findings indi-
cate that the expression of mutant PS1 or mutant
APPin PC12 cells sensitizes cells to apoptosis (Guo
et al., 1997; Eckert et al., 2001c; Marques et al., 2003).
Furthermore, cultures of primary neurons from PS1
mutant knock-in mice (PS1 M146KI) and from trans-
genic mice bearing human mutant PS1 M146Lshow
increased vulnerability to cell death (Guo et al.,
1999a; Guo et al., 1999b). In addition, lymphocyte
cell lines (e.g., the human Jurkat T-cell line), trans-
fected with mutant PS1 (Wolozin et al., 1998), and
lymphocytes from FAD patients bearing PS1 muta-
tions (Parshad et al., 1996) show similar results in
regard to increased vulnerability to DNA damage
leading to accelerated cell death. Moreover,
enhanced vulnerability to cell death has also been
described in peripheral lymphocytes from AD
patients (Hartwig, 1995; Parshad et al., 1996; Eckert
et al., 1998; Eckert et al., 2001a) but not in patients
with vascular dementia (Hartwig, 1995; Eckert et
al., 2001a). Oxidative stress mechanisms seem to
influence this process (Gibson et al., 2000; Eckert et
al., 2001a; Mecocci et al., 2002). In order to close the
gap between studies using neuronal cell lines trans-
fected with PS1 mutations, neurons from mutant
PS1 transgenic animals, and peripheral cells of AD
patients, we recently investigated lymphocytes from
mice transgenic for FAD specific PS1 mutations.
Importantly, lymphocytes from mice bearing
mutant PS1 exhibited a similar hypersensitivity to
apoptosis as do lymphocytes from AD patients
(Eckert et al., 2001b). Thus, this animal model of
AD successfully mimics common alterations in
sensitivity to cell death as seen in neurons and
peripheral cells from AD patients.
Analyses of the distribution of pathological
changes in AD suggest that this disease affects
selected populations of neurons within the cere-
bral cortex, whereas other neuronal subgroups
are remarkably resistant to the degenerative process.
Currently, no clear evidences for a predominant
expression of APP or PS1 in the affected neurons,
which might contribute to the cell type-specific vul-
nerability, have been provided. Several brain
regions (e.g., hippocampus and cerebellum) express
high levels of APPor PS1 within their neurons (Arai
et al., 1991; Page et al., 1996; Mathews et al., 2000)
but are affected differently by neurodegeneration.
Based on these findings, we investigated the vul-
nerability of specific subgroups of peripheral
Alzheimer’s cells to cell death and the susceptibil-
ity pattern in sporadic and familial forms of the dis-
ease. It would be helpful to have a peripheral model
(e.g., similar types of cells originating from the same
individual with either sensitivity or resistance to
apoptotic cell death). For this reason, we included
in our study—in addition to sporadic AD patients—
the use of young transgenic mice (3 mo old) bear-
ing Alzheimer-specific mutations (shown to be
suitable for this experimental attempt) (Eckert et al.,Cell Death in AD 163
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2001b) and investigated the sensitivity threshold for
the induction of apoptosis in T-cell subpopulations.
In addition, we included transgenic mice bearing
either mutant APPor mutant APH, and mutant PS1.
Moreover, age-related elevations of apoptotic cell
death were detected in human and murine lym-
phocytes (Schindowski et al., 2000). Studying lym-
phocytes from young mice bearing FAD mutations
has the advantage to investigate solely the impact
of genetic AD factors on cell death vulnerability by
excluding potential effects raised by aging. Our
attempt to search for cell type-specific altera-
tions in the cell death sensitivity of lymphocytes
affected by aging, sporadic, or genetic risk factors
may help to differentiate common and divergent
mechanisms of changes in the susceptibility to apop-




Twenty-six patients (9 men and 17 women) with
AD were studied. Dementia was diagnosed accord-
ing to ICD-10. Diagnosis of Alzheimer’s disease was
achieved following the guidelines of the National
Institute of Neurological and Communicative Dis-
orders and Stroke- Alzheimer’s Disease and Related
Disorders (NINCDS-ADRDA criteria) task force.
Furthermore, a MRI scan for structural imaging and
HMPAO-SPECT or FDG-PET for functional neu-
roimaging were included. The mean age was 70.9
± 9.1 yr (range 52 to 89 yr). The majority of cases
exhibited mild to moderate dementia. The mean
Mini Mental State Examination (MMSE) score was
18.6 ± 5.6 and the mean Global Deterioration Score
(GDS) was 4.1 ±1.0. FAD patients could be excluded
by patient history. Blood cells from 21 nondemented
individuals of similar age (mean age 73.2 ± 7.5 yr,
range 60 to 85 yr, 8 men and 13 women) were used
as controls (average MMSE 29 ± 0.5). As a result of
methodological reasons, only a subgroup of patients
and sex- and age-matched nondemented controls
(n = 12, 4 men and 8 women; mean age 69.8 ± 6.6 yr)
was available for stimulation experiments with lym-
phocytes. In addition, young subjects (4 men and
7 women; age under 35 yr, mean age 25.4 ± 5.1 yr)
were included within the study. Majority of AD
patients and aged controls were treated with drugs,
primarily for cardiovascular disease, but did not
receive medications known to interact with lym-
phocyte functions, or psychotropic medication. Sub-
jects with acute infections or immunological
alterations according to the SENIEUR protocol
(Ligthart et al., 1984) were not included in the study.
The study was approved by the responsible Ethical
Committee and written informed consent from all
subjects was received, where appropriate, from their
caregivers.
Generation and Characterization 
of Transgenic Mice
Generation and expression analysis of transgenic
mice was described in detail previously (Leutner et
al., 2000; Wirths et al., 2001). In brief, the coding
regions of human wild-type PS1 (PS1 wt) or PS1
M146L were introduced into a genomic construct
with the promotor of the murine 3-hydroxy-3-
methyl-glutaryl CoAreductase gene (HMG-CR) that
shows a strong and ubiquitous expression pattern
in peripheral tissues and in the brain (Leutner et al.,
2000). The generation of PDGFβ-APP695 SDLmice
has been described in detail previously (Wirths et
al., 2001). Three different FAD mutations (SDL:
Swedish mutation KM670/671NL, Dutch mutation
E693Q, London mutation V717I) have been intro-
duced in the human APP695 sequence. APPexpres-
sion was under the control of PDGFβ promotor,
which induces clear expression of human APP in
lymphocytes from APP695SDLmice. Additionally,
double transgenic mice were generated by crossing
PS1 M146L with APP695SDL mice. Transgenic
(n = 6 for all groups) and nontransgenic age and
sex-matched control animals (n= 6) were employed
at an age of 3 mo. Animals were handled according
to French and German guidelines for animal care.
Isolation of Lymphocytes
Blood from patients and control subjects was col-
lected between 8:00 and 10:00 AMto avoid influence
by circadian rhythm. Peripheral blood lymphocytes
were separated from heparinized blood by cen-
trifugation on Ficoll-Hypaque density gradient for
400g for 40 min as described previously (Schin-
dowski et al., 2000).
Because large quantities of T cells have to be
obtained from each animal for our experimental164 Schindowski et al.
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design, lymphocytes were isolated from the spleen
instead of circulating blood. In a previous study, we
demonstrated that murine lymphocytes from blood
and spleen behave similar in respect to cell death
vulnerability (Eckert et al., 2001b). Spleen cell sus-
pensions were prepared by mechanical dissociation
of individual murine spleens. Red blood cells were
lysed in hypotonic buffer as described previously
(Eckert et al., 2001b).
Expression of Human PS1 and Human APP
For Western blotting, protein extracts from T lym-
phocytes isolated from the spleens of transgenic
(PS1wt, PS1 M146L, APP695SDL) or nontransgenic
littermate control mice were prepared. After sodium
dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), PS1 proteins were identified by
immunoblotting using the human-specific antibody
MAB1563 (Chemicon) as described previously (Leut-
ner et al., 2000) (Fig.1A). For human APP, the lysate
was separated on an 8% SDS-polyacrylamide gel.
The gel was blotted into nitrocellulose membrane
and human APPwas detected with polyclonal anti-
serum 5313 recognizing only human APP (Fig.1B).
Induction of Apoptosis
Cells were investigated for apoptosis directly
after isolation (termed basal in vitro apoptosis).
Cells were plated in 48-well plates at a density of
5 ×105cells/mLand were incubated in the presence
or absence of a cell death-inducing agent (2-deoxy-
D-ribose, d-Rib, Sigma, 10 mmol/L) for 24 h.
Antibodies and Dyes for Flow Cytometry
The mouse monoclonal antibodies specific for
human antigens used in this study included: anti-
CD3 (clone SK7), anti-CD19 (clone 4G7), anti-CD4
(clone SK3), anti-CD8 (clone SK1) and isotype con-
trol IgG1(clone X40). Monoclonal antibodies specific
for murine T cell subsets: anti-mouse CD3 (145-2C11),
anti-mouse CD4 (L3T4)(RM4-5), anti-mouse CD8
(Ly-2) (53-6.7). All antibodies were obtained from
Fig. 1. Expression of human APP and human PS1 in transgenic mice. (A) Western blot analysis of PS1 expres-
sion (50 µg protein per lane). Expression of human PS1 is not observed in T lymphocytes from nontransgenic con-
trol mice (lane 3). The amino-terminal fragment of PS1 is detectable in all groups of transgenic mice (lane 1 = PS1
M146L; lane 2 = PS1wt) whereas full-length PS1 is only slightly visible in mice expressing mutant PS1 (lane 1).
Representative Western blot analysis of lymphocytes from individual mice is shown. Immunoblotting with an anti-
actin antibody (lower panel) confirmed equal protein loading. (B) Intracellular APP from cell lysates of T lym-
phocytes. Equal amounts of protein (50 µg per lane) were loaded on a 8% SDS-polyacrylamide gel. Multiple bands
reflect different splice isoforms and different posttranslational modifications of APP (indicated on the right). T lym-
phocytes from transgenic mice bearing mutant APP695SDL (lanes 3–5) show clear expression of human APP in
contrast to nontransgenic control mice (lanes 1 and 2). As a control, the blot was probed with an actin antibody
(lower panel).Cell Death in AD 165
NeuroMolecular Medicine Volume 4, 2003
Becton Dickinson/Pharmingen, Heidelberg, Ger-
many. 7-Aminoactinomycin D (7-AAD) was pur-
chased from Molecular Probes (Leiden, The
Netherlands).
Staining of Whole Blood for the Detection
of Subset Distribution
Whole blood was stained with the appropriate
antibodies following the manufacturer’s manual.
Samples were analyzed using Simulset software
(BD). Forward (FSC) and side (SCC) angle scattered
light-gating excluded debris, granulocytes, and
monoytes. For each sample, 10,000 events were
acquired.
Quantification of Total Lymphocyte Number
in Whole Blood Using TrueCount™
Absolute number of lymphocytes were deter-
mined with TrueCount beads (BD: Lot 60158, counts
46900) and CD3-PerCP, CD8-PE, and CD4-FITC
according to the manufacturer’s manual using True-
Count Absolute Count Tubes (Becton Dickinson,
Germany). Absolute cell number was calculated
using the following equation: no. of events in
cell population region (CD3, CD4 or CD8)/no. of
events in bead region × 46900 beads/test volume
(50 µL) = cells/µL
Detection of Apoptosis in Lymphocyte
Subsets by Flow Cytometry
The actinomycin D analog, 7-AAD, is able to bind
to GC regions of the DNA. During the cell death
process, the plasma membrane becomes permeable
to dye. In addition to readily quantifying apopto-
sis, 7-AAD staining offers the advantage of dis-
criminating between early and late apoptotic cells.
Staining with 7-ADD can be combined with other
staining procedures to study apoptosis in a multi-
parametric approach at a single cell level (Lecoeur
et al., 2002). Lymphocytes were triple stained
with FITC-conjugated anti-CD4 (FL-1 channel),
PE-conjugated anti-CD8 antibody (FL-2 channel),
and the nuclear dye 7-AAD. 1 µL of each antibody
and 7-AAD (6 µmol/mL) (Schmid et al., 1994) were
added to the 48-well plates for 20 min at room tem-
perature. Cells were harvested, washed twice with
PBS, resuspended in CellWASH™ (Becton Dickin-
son, Germany), and kept in the dark before flow
cytometry analysis. Debris and monocytes were
excluded by Forward (FSC) and Side (SSC) angle
scattered light gating. A total of 10,000 individual
nuclei per measurement was analyzed in each exper-
iment providing valid quantitative data. For deter-
mination of apoptotic cells, two-parameter dot plots
(FITC, PE) showing surface antigens staining (CD4-
FITC and CD8-PE) were then created and each
subset was marked with a distinct color. Gated cells
were displayed in a new dot plot showing FSC plot-
ted against 7-AAD (FL-3 channel). Living, early, and
late apoptotic cells were defined according to the
level of 7-AAD staining (labeled “live,” “apoptotic”
and “dead” within dot plots) (Lecoeur et al., 2002).
Statistics
Data are given as mean ±SEM. For statistical com-
parison, Student’s t-test, one-way ANOVAfollowed
by Tukey’s post hoc test or two-way ANOVAwere
utilized. p Values less than 0.05 were considered to
be statistically significant.
Results
Expression of Mutant Alzheimer’s Genes 
in Lymphocytes From Transgenic Mice
The transgenic mice used in the present study
have been previously characterized for expression
of the human transgene in their brains (Leutner et
al., 2000; Wirths et al., 2001). To study effects of
genetic FAD risk factors on cell death vulnerability
in lymphocytes, these cells have to meet the basic
requirements of expression of mutant APP and/or
PS1 that appear to be ubiquitously expressed
throughout the human body. Transgene expression
of human PS1 is under control of a modified HMG-
CoA reductase promoter. This housekeeping-type
promoter shows a strong and ubiquitous expres-
sion pattern with high expression in neurons (Leut-
ner et al., 2000). In order to assess human PS1
expression, we performed Western blot analysis of
cell lysates from T lymphocytes of transgenic mice
and nontransgenic littermate controls. The Western
blot was probed with a human-specific monoclonal
antibody (MAB1563, Chemicon) directed against
the amino-terminal part of PS1 for the detection of
full-length PS1 and N-terminal fragments. This anti-
body is specific for human PS1, because no signal166 Schindowski et al.
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of the endogenous PS1 is detectable in the lysate of
the nontransgenic mice (Fig.1A, lane 3). Transgenic
mice bearing either human PS1 wt or mutant PS1
M146Lshowed clear expression of the transgene in
their T lymphocytes (Fig.1A, lanes 1 and 2). In accor-
dance with our previous findings in the brains of
PS1 transgenic mice (Leutner et al., 2000), expres-
sion of human PS1 was higher in PS1 M146L mice
compared to PS1 wt mice and small amount of full-
length PS1 was detectable in PS1 M146L mice
(Fig. 1A, lane 1). Given that the comparison of two
different mutant PS1 transgenic lines with either
low or high expression of human PS1 to the wt PS1
line showed that mutations in PS1, and not simple
overexpression of the transgene, caused alterations
in the vulnerability to cell death (Eckert et al., 2001b),
PS1 expression level may not be responsible for the
cellular changes described in the following section.
Transgene expression of human APP is under
control of the PDGF promoter (Wirths et al., 2001).
For detection of human APP, the human-specific
rabbit antiserum 5313 was used (Eckert et al., 2001c).
As expected, in mice bearing the human APPtrans-
gene, Western blotting revealed a clear expression
of the transgene in lymphocytes from transgenic
mice (Fig.1B, lanes 3–5), whereas the antiserum did
not recognize any APPspecies in the nontransgenic
littermate controls (Fig.1B, lanes 1 and 2).
Thus, we could demonstrate a clear expression
of both, human APP and PS1, in T cells from trans-
genic mice indicating that their lymphocytes can be
used to study the effects of FAD mutations on cell
death vulnerability or other cellular function.
Human APP or PS1 revealed a similar expression
pattern in mice as did endogenous APPor PS1 with
a higher expression level in the brain than in non-
neuronal cells (data not shown). A comparable
expression pattern has also been found in man (Arai
et al., 1991; Page et al., 1996).
Unchanged Pattern of Lymphocyte Subset
Distribution in AD, But Age-Related
Decrease of T Cells
Recently, we were able to show that peripheral
lymphocytes exhibit an age-related increase in vul-
nerability to apoptosis compared to young controls
(Schindowski et al., 2000). This enhanced suscepti-
bility was even more pronounced in lymphocytes
from sporadic AD patients compared to nonde-
mented aged controls (Eckert et al., 1998; Eckert et
al., 2001a). Therefore, it was necessary to clarify
whether these changes can be explained by the
hypersensitivity of one specific lymphocyte subset
only. To avoid misinterpretation of an enhanced
apoptosis owing to changes in the distribution pat-
tern of lymphocyte subsets with distinct sensitivity
thresholds for the induction of cell death, we inves-
tigated the distribution of lymphocyte subsets in
young subjects, nondemented aged controls, and
AD patients. 
The lymphocyte population mainly consists of
T cells. Thus, changes in the percentage of
T lymphocytes and/or their subsets may influence
the total apoptotic balance in lymphocytes. In our
present study, distribution of lymphocyte subsets
was not altered among AD patients and nonde-
mented controls (CD3+ cells [T cells]: 69.8 ± 1.9% in
AD patients vs 66.0 ± 2.2% in controls; CD19+ cells
[B cells]: 10.3 ± 0.85 in AD patients vs 10.9 ± 1.2 in
controls). In contrast, the distribution pattern during
aging is altered showing a slight decrease of T cells
(CD3+ cells: 73.0 ± 1.5%, p < 0.01 vs aged controls;
CD19+ cells: 11.8 ± 0.9%). To further investigate the
distribution of T lymphocyte subpopulations, we
counted the absolute cell number of CD3+ T cells as
well as CD4+ and CD8+ T cells in the whole blood
(Fig. 2A,B). Again, no differences were found
between AD patients and nondemented aged con-
trols, but a significant loss of CD3+, CD4+, and CD8+
T cells occurred during aging (Fig. 2C). However,
CD4+, and CD8+ T-cell decline seems to be equally
affected by aging, because CD4/CD8 ratio was
unaltered. No differences in the distribution of
lymphocyte and especially T-lymphocyte subsets
were found in AD, thus we can exclude that this is
a causative factor for the altered vulnerability to cell
death found in the total population of peripheral
lymphocytes from AD patients.
Evaluation of Apoptotic Cell Death 
in T-Lymphocyte Subsets
Next, we evaluated apoptotic cell death in
T-lymphocyte subsets by flow cytometry analysis
using instrument settings specific for the detection
of apoptotic DNAfragments. The portion of apop-
totic cells was quantified in CD4+ or CD8+ labeledCell Death in AD 167
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Fig. 2. Analyses of the composition of lymphocyte subsets. (A,B) Quantification of total lymphocyte number in
whole blood using TrueCount®. Absolute number of lymphocytes was determined with TrueCount® beads (B,D)
and triple-stained lymphocytes (CD3-PerCP, CD8-PE, and CD4-FITC). CD3+T cells were gated (A) and subsequent
CD4+ and CD8+T cell analysis was only performed with CD3+ positive T cells (B) and related to bead counts. (C)
Changes of T lymphocyte subsets in aging and AD. Absolute cell number of CD3+ T cells plus CD4+ and CD8+
T cells was determined in the whole blood. No differences were found between AD patients and nondemented
aged controls, but a significant loss of CD3+, CD4+, and CD8+ T cells in aging (ANOVA post hoc Tukey’s test:
CD3+: §§ p < 0.01 vs CD3+ from aged controls, &&p < 0.01 vs CD3+ from AD patients; CD4+: ++p < 0.01 vs CD4+
from aged controls, *p < 0.05 vs CD4+ from AD patients; CD8+: $$p < 0.01 vs CD8+ from aged controls,
##p < 0.01 vs CD8+ from AD patients). Color image available for viewing at www.humanapress.com.168 Schindowski et al.
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T cells using a co-staining technique with the fluo-
rescent dye 7-AAD (Fig. 3A). We determined the
accumulation of apoptotic cells under basal condi-
tions or after 24 h in vitro incubation in the absence
or presence of cell death triggering agents. For the
activation of cell death, we used 2-deoxy-D-ribose
(d-Rib), that is known to trigger apoptosis in lym-
phocytes by depletion of the intracellular pool of
reduced glutathione thereby producing oxidative
stress (Kletsas et al., 1998).
Basal In Vitro Apoptosis
To investigate the effects of aging and sporadic
or genetic risk factors of AD on vulnerability to cell
death in T-lymphocyte subsets, we studied isolated
peripheral lymphocytes from young or aged non-
demented controls and from sporadic AD patients
on the one hand and lymphocytes from the
spleens of transgenic mice bearing Alzheimer’s
mutations in PS1 and/or APP on the other hand.
The latter model was used, because we already
demonstrated that T cells from PS1 transgenic mice
exhibited a similar hypersensitivity to cell death
than did lymphocytes from AD patients (Eckert et
al., 2001b). In addition, by investigating young mice,
we can avoid potential overlapping effects as a result
of aging.
In flow cytometry analysis, freshly isolated T cells
from aged controls showed a significant increase in
basal in vitro apoptosis of both, CD4+ as well as
CD8+T cells, compared to the T-cell subsets of young
control subjects (Fig. 3B). In contrast, AD patients
showed a highly significantly enhanced basal in
vitro apoptosis only of CD4+T cells when compared
to cells from nondemented aged control subjects
(Fig. 3B). CD8+ T cells from AD patients showed a
similar, but not significant tendency with regard to
slightly elevated levels of apoptotic cells when com-
pared to control cells (Fig. 3B). In parallel, CD4+
T cells from mice expressing mutant PS1 (PS1
M146L) and/or mutant APP (APP695 SDL) exhib-
ited significantly enhanced levels of apoptotic cells
compared to CD4+ T cells from PS1 wt Tg and non-
transgenic controls (Fig. 3C). The same effects could
be additionally observed in CD8+T cells from trans-
genic mice bearing mutant APPor PS1, even though
the maximum of the apoptotic proportion in CD8+
T cells was less than in CD4+ T cells from all groups
of mice. There was no significant difference between
CD8+T cells from double transgenic APP/PS1 mice
and control mice. This is probably because of the
Fig. 3. (see opposite page) Detection of apoptosis in lymphocyte subsets by flow cytometry and Alzheimer-
related changes of basal in vitro apoptosis (A) Determination of apoptotic cells with triple staining using 7-AAD
and monoclonal antibodies against T lymphocyte subsets CD4 and CD8. CD4 (FL-1 channel) and CD8 (FL-2 chan-
nel) positive cells (a), respectively, were gated and displayed in a new dot plot showing 7-AAD fluorescence vs
forward scatter light (b,c). Living, early and late apoptotic cells were defined according to the level of 7-AAD
staining (labeled “live, apoptotic and dead” within dot plots). (b) shows the determination of apoptotic cells of
gated CD4+ T lymphocytes, (c) shows the determination of apoptotic cells of gated CD8+ T lymphocytes. (B) (a)
Basal apoptosis in CD4+T cells and in CD8+ T cells from young subjects (n = 11), elderly nondemented controls
(n = 21), and AD patients (n = 26). CD4+T lymphocytes from AD patients showed significantly elevated levels of
basal apoptotic cells compared to nondemented controls (ANOVA post hoc Tukey’s test: **p < 0.01 vs CD4+ from
young and aged controls). Basal apoptosis was elevated in CD4+T cells as well as in CD8+T cells from aged con-
trols compared to young ones (ANOVA post hoc Tukey’s test: +p < 0.05 vs CD4+ from young controls, #p < 0.05
vs CD8+ from young controls). Two-way ANOVA revealed significant differences between groups (p < 0.001).
(b–d) Representative dot blots of individual subjects showing determination of basal apoptosis by 7-AAD mea-
surement in CD4+T cells from young control (b), aged control (c), and AD patient (d). (C) Basal apoptosis in CD4+
T cells and in CD8+T cells from nontransgenic controls and from transgenic mice expressing either mutant human
APP (APP695SDL) or mutant human PS1 (PS1 M146L), or both, or human wild-type PS1 (PS1 wt) (n = 6 for all
groups). T cells bearing FAD-associated mutations displayed significantly elevated levels of basal apoptotic cells
compared to PS1 wt or nontransgenic controls (ANOVA post hoc Tukey’s test: *p < 0.05 vs CD4+ from control;
+p < 0.05, ++p < 0.01 vs CD4+ from PS1 wt, #p < 0.05 vs CD8+ from control; $p < 0.05 vs CD8+ from PS1 wt,
n = 6). The absolute increase in apoptosis was higher in CD4+ T cells than in CD8+ T cells: two-way ANOVA
revealed significant differences between mice groups (p < 0.001) and the lymphocyte subsets (p < 0.001).170 Schindowski et al.
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Fig. 4. Alterations of spontaneous apoptosis in aging and Alzheimer’s disease (A) Spontaneous in vitro apopto-
sis in CD4+ T cells and in CD8+ T cells from young subjects (n = 11), nondemented controls (n = 12), and AD
patients (n = 12) after 24 h in vitro incubation. Again, CD4+T cells from AD patients showed a highly significantly
increased spontaneous apoptosis compared to control subjects (ANOVA post hoc Tukey’s test: **p < 0.01 vs CD4+
from aged controls; ***p < 0.001 vs CD4+ from young controls), whereas CD8+T cells did not differ. Spontaneous
apoptosis was elevated in CD4+ T cells as well as in CD8+ T cells from aged controls compared to young onesCell Death in AD 171
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high variance of apoptotic levels in APP/PS1 T lym-
phocytes within this experiment. 
Taken together, these findings indicate that espe-
cially the increased susceptibility of CD4+ T cells
from sporadic AD patients as well as from FAD
transgenic mice mainly contributes to the total vul-
nerability of T lymphocytes, whereas the hyper-
sensitivity of both cell types appears to participate
in the total vulnerability of aged lymphocytes.
Spontaneous In Vitro Apoptosis
Next, we studied apoptosis after 24 h in vitro
incubation termed spontaneous apoptosis. Again,
apoptosis was increased in CD4+ T cells as well as
in CD8+ T cells from aged controls compared to
young ones (Fig. 4A). Notably, also in this para-
digm, exclusively CD4+ T cells from AD patients
showed a highly significantly enhanced sponta-
neous apoptosis compared to CD4+T cells from non-
demented aged control subjects (Fig. 4A), whereas
CD8+ T cells from AD patients did not (Fig. 4A).
Similarly, CD4+T cells from mice expressing mutant
PS1 (PS1 M146L) and/or mutant APP(APP695 SDL)
exhibited significantly enhanced basal levels of
apoptotic cells compared to CD4+ T cells from PS1
wt Tg and nontransgenic littermate controls (Fig.
4B). Also under these conditions, increased apop-
tosis was identified in CD8+ T cells from transgenic
mice bearing mutant APP and/or PS1 (Fig. 4B).
Again, CD8+ T cells exhibited apoptosis to a lesser
degree as did CD4+ T cells from all groups of mice
confirming our observations of the apoptotic behav-
ior under basal conditions (Fig. 3C).
Oxidative Stress-Induced Apoptosis
To investigate the induction of apoptosis under
conditions mimicking oxidative stress, we stimu-
lated T lymphocytes with d-Rib for 24 hr in vitro.
Again, apoptosis was increased in CD4+ T cells as
well as in CD8+T cells from aged controls compared
to young ones (Fig. 5A). There was a slight, nonethe-
less cell type-specific increase in d-Rib-induced
apoptosis in CD4+T cells from sporadic AD patients
compared to nonaffected controls that was not pre-
sent in CD8+ T cells. However, this effect failed to
reach statistical significance (p = 0.06) (see Fig. 5A).
Expression of mutant APP and/or PS1 in CD4+
T cells resulted in a significantly increased levels
of apoptotic cells after exposure to oxidative stress
compared to CD4+ T cells from PS1 wt Tg and non-
transgenic controls (Fig. 5B), whereas CD8+ T cells
reacted again much less sensitive (Fig. 5B). These
findings further emphasize the cell type-specific
sensitivity of CD4+ T cells to the induction of apop-
totic cell death in AD.
Discussion
Enhanced vulnerability to cell death appears to
be an important factor of aging and age-related spo-
radic AD. Although, histological studies in post-
mortem AD brain tissue indicate enhanced features
of apoptotic cell death, such as DNAfragmentation
(Cotman, 1998; Stadelmann et al., 1999), evidences
for an enhanced cellular vulnerability to the induc-
tion of apoptosis primarily originate from studies
Fig. 4. (continued) (ANOVA post hoc Tukey’s test: ++p < 0.01 vs CD4+ from young controls, #p < 0.05 CD8+
from young controls). Two-way ANOVA revealed significant differences between groups (p < 0.001) and the lym-
phocyte subsets (p < 0.01; AD CD4+ vs AD CD8+: p < 0.01). (b–c) Representative dot blots of individual subjects
showing determination of spontaneous in vitro apoptosis by 7-AAD measurement in CD4+T cells from young con-
trol (b), aged control (b), and AD patient (d). (B) Spontaneous in vitro apoptosis in CD4+ T cells and in CD8+
T cells from nontransgenic controls and from transgenic mice expressing either mutant human APP (APP695SDL)
or mutant human PS1 (PS1 M146L), or both, or human wild-type PS1 (PS1 wt) (n = 6 for all groups). Both, CD4+
and CD8+T cells, bearing FAD-associated mutations displayed significantly elevated levels of apoptotic cells after
24 h incubation compared to PS1 wt or nontransgenic controls (ANOVA post hoc Tukey’s: *p < 0.05, **p < 0.01
vs CD4+ from control; ++p < 0.01, +++p < 0.001 vs CD4+ from PS1 wt; #p < 0.05, ##p < 0.01 vs CD8+ from con-
trol; $$p < 0.01, $$$p < 0.001 vs CD8+ from PS1 wt, n = 6). Again, apoptosis was more pronounced in CD4+ cells:
two-way ANOVA revealed significant differences between mice groups (p < 0.001) and the lymphocyte subsets
(p < 0.001). 172 Schindowski et al.
Fig. 5. Changes of oxidative stress-induced apoptosis in aging and Alzheimer’s disease. (A) Apoptosis in CD4+
T cells and in CD8+T cells from young subjects (n = 11), nondemented controls (n = 12), and AD patients (n = 12)
after exposure to oxidative stress. Cell death was triggered in vitro by treatment with d-Rib (10 mM) for 24 h. Apop-
totic cell death in CD4+T cells from AD patients tended to higher levels compared to nondemented aged controls
(ANOVA post hoc Tukey’s test: **p < 0.01 vs CD4+ from young controls; (*)p = 0.06 vs CD4+ from aged controls,
student’s t-test), whereas apoptosis in CD8+ T cells did not differ. d-Rib-induced apoptosis was elevated in CD4+
T cells as well as in CD8+ T cells from aged controls compared to young ones (ANOVA post hoc Tukey’s test: +P
< 0.05 vs CD4+ from young controls, #p < 0.05 vs CD8+ from young controls). Two-way ANOVA revealed signif-
icant differences between groups (p < 0.01) and the lymphocyte subsets (p < 0.05; AD CD4+ vs AD CD8+: p <
0.01). (B) Apoptosis in CD4+ T cells and in CD8+ T cells from nontransgenic controls and from transgenic mice
expressing either mutant human APP (APP SDL) or mutant human PS1 (PS1 M146L), or both, or human wild-type
PS1 (PS1 wt) after exposure to oxidative stress (n = 6 for all groups). Cell death was triggered in vitro by treatment
with d-Rib (10 mM) for 24 h. CD4+T cells bearing mutant PS1, and/or APP displayed significantly elevated levels
apoptotic cells compared to PS1 wt or nontransgenic controls (ANOVA post hoc Tukey’s test: *p < 0.05 vs CD4+
from control, n = 6). In CD8+T cells from the same transgenic mice, a similar tendency to elevated apoptosis could
be observed, again to a lesser extent when compared to the corresponding CD4+T cells: two-way ANOVA revealed
significant differences between mice groups (p < 0.001) and the lymphocyte subsets (p < 0.01).Cell Death in AD 173
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using lymphocytes from sporadic AD patients (Par-
shad et al., 1996; Eckert et al., 1998; Mecocci et al.,
2002). The use of these easily accessible cells from
AD patients complements studies of autopsy sam-
ples in a meaningful matter and provides a useful
tool to investigate dynamic processes such as the
regulation of cell death pathways, signal transduc-
tion mechanisms, intracellular calcium regulation,
and oxidative metabolism (Mecocci et al., 1994;
Gibson et al., 1996; Eckert et al., 1998; Gibson et al.,
2000; Mattson et al., 2001; Eckert et al., 2001a; Gibson
et al., 2002; Mecocci et al., 2002). Abnormalities in
each of these processes occur in AD and can be linked
to neuronal death and brain dysfunction. Some of
these pathological changes are also related to aging
and are additionally altered in AD by common or
divergent mechanisms (Quadri et al., 1996; Poulin
et al., 1996; Eckert et al., 1997a; Eckert et al., 1997b;
Schindowski et al., 2000). Cell culture experiments
also suggest that defects in the cellular calcium
stores, ability to handle oxidative stress, and to
respond to metabolic impairment, link the FAD-
causing PS1 mutations to the disease process (Matt-
son et al., 2001). Importantly, our recent findings in
lymphocytes from PS1 mutant transgenic mice
mirror comparable findings in lymphocytes from
AD patients (Parshad et al., 1996; Eckert et al., 1998;
Eckert et al., 2001a) indicating that disturbances in
the metabolism of ROS inside cells, abnormal cal-
cium homeostasis, and increased susceptibility to
cell death may contribute to the pathogenic mech-
anisms of PS-1 mutations in vivo. Accordingly, evi-
dence supports a similarly increased vulnerability
to oxidative stress-induced DNA damage present
in lymphocytes from FAD patients bearing PS1
mutations (Parshad et al., 1996).
Because a difference in the distribution pattern
of lymphocyte and particularly T lymphocyte sub-
sets between AD patients and nondemented con-
trols was not observed, it can be concluded that
CD4+T cells mostly contribute to the increased apop-
totic cell levels found in peripheral lymphocytes
from AD patients (Eckert et al., 1998; Eckert et al.,
2001a). This defect itself appears not to be sufficient
to lead to a pathological leukopenia in AD patients
probably owing to the rapid restoration process of
deleted lymphocytes, a balanced regulation that is
clearly not possible for the affected brain cells.
Whereas in AD brain the accumulation of Aβ and
oxidative damage put neuronal cells under chronic
stress for many years, the lack of these accumula-
tion processes in the periphery may also explain
why massive cell loss is not observed in circulating
blood cells or fibroblasts.
One major concern regarding the hypothesis of
common alterations in the brain and immune system
relates to the observation that the spatial patterns
of lesions in AD brain may reflect pathological
processes affecting particular neuroanatomical
structures or susceptible neuronal subpopulations,
whereas other neuronal subgroups are strikingly
resistant to cell death (Armstrong et al., 2001).
In the present study, we clearly demonstrate that
in the immune system specific subpopulations of the
same cell type are more vulnerable to cell death than
others. CD4+T cells from sporadic AD patients exhib-
ited strong disease-specific alterations in the vul-
nerability to cell death compared to CD4+T cells from
aged nondemented controls, whereas no differences
in the susceptibility of CD8+T cells to apoptosis have
been found for all conditions investigated. As demon-
strated previously, our assay investigating vulnera-
bility of lymphocytes to cell death appears to possess
specificity for AD, because patients with vascular
dementia did not show an increased susceptibility
to apoptosis (Eckert et al., 2001a). However, there is
some overlap in apoptotic levels of CD4+ cells
between AD patients and controls. Therefore, it
would be very interesting to investigate the risk for
AD of these subjects during a longitudinal study.
Consistent with this observation, FAD mutations
also increase vulnerability of CD4+ T cells to apop-
tosis. The same tendency was evident in CD8+
T cells but to a lesser degree. Thus, sporadic risk
factors of AD exhibit the highest impact on cell type-
specific increase in the sensitivity of CD4+ T cells to
cell death. Nevertheless, genetic factors prefer-
entially impact the same specific cell type as well
as do sporadic factors. In contrast, the age-related
elevation of apoptotic cell death was not cell type-
specific, given that increased apoptosis was char-
acteristic for both, CD4+and CD8+T cells from aged
controls. Only age-related enhanced vulnerability
of CD4+T cells can be further heightened by AD but
not that of CD8+ T cells (Schindowski et al., 2002).
Aging represents the most important risk factor for
sporadic AD, thus, it may also directly contribute
to the same final pathway in CD4+ T cells. 
Why do CD4+ T cells from AD patients exhibit
this cell type-specific increase in the vulnerability174 Schindowski et al.
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to cell death? Several experimental studies provide
support for an AD-specific cause-effect relationship
between increased susceptibility of CD4+T cells and
other pathological changes probably involved in
cellular dysfunction and cell death. For example,
our results support findings that serum levels of
CD95 (Fas, Apo-1), known to mediate apoptosis, are
elevated in AD patients (Richartz et al., 2002).
Indeed, preliminary findings of our group indicate
that CD4+ T cells from AD patients are more vul-
nerable to the induction of apoptosis by Fas-ligand
(FasL) than CD4+ T cells from aged nondemented
controls (AD: 25.8% ± 7.0% vs Co 12.2 ± 2.1%, n =
6; p < 0.05). In particular, there seems to be a sig-
nificant increase in Fas expression in CD4+ T cells
of AD patients (Lombardi et al., 1999) that may
explain their cell type-specific increased vulnera-
bility to apoptosis. Interestingly, these findings are
also in agreement with data demonstrating that Fas
is involved in inflammatory processes in AD brain.
Thus, increased soluble Fas concentrations have
been found in the cerebrospinal fluid from AD
patients compared with nondemented controls
(Martinez et al., 2000). The accumulation of Aβmay
also lead to cross-linking and activation of death
receptors, such as Fas, resulting in caspase activa-
tion and neuronal cell death in AD brain (Ivins et
al., 1999). In addition, Fas antigen is expressed by
a subset of reactive astrocytes in AD patients and
may play a pivotal role in governing astrocyte apop-
totic or inflammatory responses (Saas et al., 1999).
Moreover, growing evidence suggests that mutant
PS1 and/or mutant APP sensitize cells to apopto-
sis, by linking perturbed calcium homeostasis to the
pathogenic action of AD-specific mutations. Again,
these changes are not limited to neurons (Mattson
et al., 1993; Parshad et al., 1996; Sulger et al., 1999;
Mattson et al., 2001; Eckert et al., 2001b; Eckert et
al., 2001c). Interestingly, different mutations in both
genes, APP and PS1, appear to have the same final
effect of an increased vulnerability to cell death in
lymphocytes. Our experiments did not support a
more pronounced vulnerability in CD4+T cells from
double transgenic mice compared to mice bearing
either PS1 or APPalone. These results provide sup-
port to our hypothesis that PS1 and APPmutations
affect the same common final pathway in lympho-
cytes, rather than different ones, because in the latter
case an additive effect of both genes would be
expected. Given that lymphocytes from transgenic
mice showed alterations in the vulnerability to the
induction of apoptosis when the animals did not
exhibit an obvious neurodegeneration or Aβ
plaques, the alterations described above may occur
independently from or may precede AD brain
pathology. Additionally, our results of an increased
cell type-specific vulnerability are in accordance
with an altered calcium regulation in CD4+ T lym-
phocytes from familial (PS1 mutations) and spo-
radic AD patients compared to lymphocytes from
age-matched controls (Grossmann et al., 1993), con-
firming the implication of this defect for all cases of
AD. Therefore, the altered calcium response in CD4+
T cells from AD patients may be related to increased
vulnerability of CD4+ T lymphocytes from AD
patients to apoptosis. Calcium mediates responses
of lymphocytes to a variety of signals, thereby reg-
ulating cell proliferation, differentiation, and cell
death. It remains to be determined how increased
Fas receptor expression, circulating factors like Fas
and Aβ (Eckert et al., 1993), and disturbed calcium
regulation in CD4+ T cells from AD patients might
result in an increased vulnerability to apoptosis of
these cells. It seems reasonable that AD-related path-
ogenic mechanisms are directly linked to the cell-
type specific change in the sensitivity threshold. 
Changes in immune cell function in AD patients,
and animal models suggest the existence of an
immunological contribution to the pathogenesis and
progression of AD. The immune system normally
plays an important role in removing toxic Aβ from
the brain as recently shown by the immunization
of transgenic mice with aggregated forms of Aβ
(Schenk et al., 1999). Human autoreactive lympho-
cytes can recognize Aβ and might therefore be
important for its elimination (Marx et al., 1998). In
addition to cytotoxic CD8+ T lymphocytes, a pop-
ulation of CD4+ T lymphocytes exists that has an
immunmodulatory role, expresses cytolytic activ-
ity (CD4+ CTL) after activation, and induces apop-
tosis in Fas-positive target cells (Hahn et al., 1995).
Activated T lymphocytes can readily cross the
endothelial blood–brain barrier. Having crossed the
blood–brain barrier , the activated T cells interact
with local glial cells by releasing factors, including
interferon-gamma and tumor necrosis factor alpha,
before undergoing apoptosis. Notably, recent find-
ings demonstrate an adverse effect of PS1 mutations
on microglial cells resulting in their hyperactiva-
tion under pro-inflammatory conditions, whichCell Death in AD 175
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may, together with direct effects of mutant PS1 in
neurons, contribute to the neurodegenerative
process in AD (Lee et al., 2002). Thus, the immune
surveillance of the central nervous system seems to
be implemented by activated T cells. The findings
of the present study may be of potential relevance
to the understanding and design of an effective
immunological approach to the diagnosis and pre-
vention of AD.
Taken together, our data support common but
also divergent mechanisms of an enhanced sus-
ceptibility of lymphocytes to apoptosis in aging and
AD. It remains to be determined exactly which defect
finally results in the cell-type specific sensitivity of
AD lymphocytes. Our findings further emphasize
the central role of enhanced cellular vulnerability
to cell death as a common pathological pathway
for sporadic and familial AD with aging possibly
playing a contributory role (Mattson, 2000). 
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